|
Gender (male/female)
|
33/185
|
Anti-nuclear antibody (ANA) (+) No.(%)
|
215 (98.6)
|
|
Age (mean ± SD) (years)
|
32.5 ± 11.3
|
Anti-double stranded DNA antibody (ds-DNA) (+) No.(%)
|
153 (70.6)
|
|
Follow-up time (median, range) (months)
|
41 (1,360)
|
Anti-SSA antibody (+) No.(%)
|
102 (46.8)
|
|
Fever (non-infectious) No.(%)
|
69 31.7)
|
Anti-SSB antibody (+) No.(%)
|
25 (11.5)
|
|
Malar rash No.(%)
|
118 (54.1)
|
Anti-Smith antibody(Sm) (+) No.(%)
|
53 (24.3)
|
|
Photosensitivity No.(%)
|
47 (21.6)
|
Anti-ribonucleoprotein (RNP) antibody (+) No.(%)
|
66 (30.3)
|
|
Oral ulcer No.(%)
|
64 (29.4)
|
Anti- cardiolipin antibody (+) No.(%)
|
16 (7.3)
|
|
Alopecia No.(%)
|
68 (31.2)
|
SLEDAI (mean ± s.d.)
|
17.6 ± 5.8
|
|
Arthralgia No.(%)
|
115 (52.8)
|
Activity indices (AI) score (median, range)
|
8 (0,19)
|
|
Serositis No.(%)
|
34 (15.6)
|
Endocapillary hypercellualrity (median, range)
|
3 (0,-3)
|
|
Neurologic disorder No.(%)
|
14 (6.4)
|
Cellular crescents (median, range)
|
0 (0,6)
|
|
Anemia No.(%)
|
147 (67.4)
|
Karyorrhexis/fibrinoid necrosis (median, range)
|
0 (0,6)
|
|
Leukocytopenia No.(%)
|
102 (46.8)
|
Subendothelial hyaline deposits (median, range)
|
1 (0,3)
|
|
Thrombocytopenia No.(%)
|
64 (29.4)
|
Interstitial inflammatory cell infiltration (median, range)
|
1 (0,3)
|
|
Hematuria No.(%)
|
168 (77.1)
|
Glomerular leukocyte infiltration (median, range)
|
1 (0,12)
|
|
Leukocyturia (non-infection) No.(%)
|
118 (54.1)
|
Chronicity indices (CI) score (median, range)
|
2 (0,10)
|
|
Acute renal failure No.(%)
|
39 (17.9)
|
Glomerular sclerosis (median, range)
|
0 (0,3)
|
|
Hemoglobin (mean ± SD) (g/l)
|
100.92 ± 26.36
|
Fibrous crescents (median, range)
|
0 (0,3)
|
|
Urine protein (median, range) (g/24 hours)
|
4.36 (0–17)
|
Tubular atrophy (median, range)
|
1 (0,3)
|
|
Serum creatinine (median, range) (μmol/l)
|
82.0 (37,1000)
|
Interstitial fibrosis (median, range)
|
1 (0,3)
|
